Henrichsmann Martina, Hempel Georg
Institute of Pharmaceutical and Medical Chemistry, Westfälische Wilhelms-University Münster, Corrensstraße 48, 48149, Münster, Germany.
Int J Clin Pharm. 2016 Feb;38(1):54-60. doi: 10.1007/s11096-015-0206-0. Epub 2015 Nov 21.
Since the new German Apothekenbetriebsordnung was released, medication therapy management (MTM) has increased in importance. MTM is intended to improve the quality of life of patients.
The aim of this study was to improve the quality of life of patients with Parkinson's disease through an MTM by a community pharmacist.
The patients were recruited in cooperation with the Deutsche Parkinson Vereinigung e.V. (dPV) in Germany. Methods All patients were evaluated at baseline (t0) and after a follow-up of 4 months (t1). During the intervention period, the pharmacists implemented an MTM with standardized pharmaceutical care. Main outcome measure The effects of the interventions were measured by the Unified Parkinson Disease Rating Scale (UPDRS) and the Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS).
In this study, 90 patients with Parkinson's disease were included. The most common intervention was to find a therapy for untreated comorbidities. The UPDRS or MDS-UPDRS improved significantly after the intervention period by a median change rate of 1 (p < 0.05) or rather 2 (p < 0.05) compared to the baseline.
The study shows that the quality of life in Parkinson's disease patients improved significantly through MTM.
自新的德国《药房经营条例》发布以来，药物治疗管理（MTM）的重要性日益增加。MTM旨在提高患者的生活质量。
本研究的目的是通过社区药剂师开展的MTM来提高帕金森病患者的生活质量。
患者是与德国帕金森病协会（dPV）合作招募的。方法：所有患者在基线时（t0）和随访4个月后（t1）进行评估。在干预期内，药剂师实施了标准化药学服务的MTM。主要结局指标：干预效果通过统一帕金森病评定量表（UPDRS）和运动障碍协会统一帕金森病评定量表（MDS-UPDRS）进行测量。
本研究纳入了90例帕金森病患者。最常见的干预措施是为未治疗的合并症寻找治疗方法。与基线相比，干预期后UPDRS或MDS-UPDRS显著改善，中位变化率分别为1（p<0.05）或2（p<0.05）。
该研究表明，通过MTM，帕金森病患者的生活质量得到了显著改善。
